title: Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis.
abstract: BACKGROUND
  The reported incidence, prevalence and outcomes of atrial fibrillation (AF) in patients with end-stage renal disease (ESRD) are variable. The risks and benefits of warfarin anticoagulation need to be defined as the risk of bleeding in ESRD patients may overwhelm the benefits of embolic stroke prevention. We undertook a systematic literature review to clarify these issues.
  
  
  METHODS
  A literature search was undertaken using Medline and EMBASE from 1990 to September 2011. Studies that reported incidence, prevalence or selected outcomes in ESRD patients with AF were included. Cross-sectional, cohort and randomized controlled trials with >25 participants were included. The lists of authors and abstracts from the search were reviewed by two investigators to determine the manuscripts for full text review. Data were abstracted to a form designed specifically for this study. The quality of the studies was assessed using the Newcastle-Ottawa scale. Event rates were calculated using a random-effects model.
  
  
  RESULTS
  Twenty-five studies met our inclusion criteria. The prevalence of AF was 11.6% and the overall incidence was 2.7/100 patient-years. The risk of mortality and stroke was increased in ESRD patients with AF at 26.9 and 5.2/100 patient-years versus 13.4 and 1.9/100 patient-years compared with ESRD patients without AF. The majority of studies do not support a protective effect for warfarin in ESRD patients with AF.
  
  
  CONCLUSIONS
  The incidence and prevalence of AF in ESRD patients are higher than in the general population and are associated with an increased risk of stroke and mortality. An appropriately designed randomized controlled trial is required to determine whether anticoagulation is an appropriate therapeutic strategy in patients with end-stage renal disease and atrial fibrillation.
authors.affiliation: Department of Medicine, Ottawa Hospital, University of Ottawa, Canada. dzimmerman@ottawahospital.on.ca
authors.forename: Deborah
authors.initials: D
authors.lastname: Zimmerman
authors.forename: Manish M
authors.initials: MM
authors.lastname: Sood
authors.forename: Claudio
authors.initials: C
authors.lastname: Rigatto
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Holden
authors.forename: Swapnil
authors.initials: S
authors.lastname: Hiremath
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Clase
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin